丁吡考胺
| 丁吡考胺 | |
|---|---|
| |
| IUPAC名 5-Butylpyridine-2-carboxamide | |
| 別名 | Sch-10595; Fusaramide[1] |
| 識別 | |
| CAS號 | 22632-06-0 
|
| PubChem | 31447 |
| ChemSpider | 29167 |
| SMILES |
|
| InChI |
|
| InChIKey | VKSPIPWLHGKJQO-UHFFFAOYAT |
| 性質 | |
| 化學式 | C10H14N2O |
| 摩爾質量 | 178.23 g·mol−1 |
| 若非註明，所有數據均出自標準狀態（25 ℃，100 kPa）下。 | |
丁吡考胺（英語：Bupicomide，化學名：5-丁基吡啶-2-酰胺，5-Butylpyridine-2-carboxamide）是一種有機化合物，化學式C10H12N2O，具有β受體阻滯劑功能，在臨床上用於血管舒張。[2][3][4]
參考文獻
[編輯]- ^ Bupicomide （頁面存檔備份，存於互聯網檔案館）, Chemical Book
- ^ Chrysant, SG; Adamopoulos, P; Tsuchiya, M; Frohlich, ED. Systemic and renal hemodynamic effects of bupicomide: A new vasodilator. American Heart Journal. 1976, 92 (3): 335–9. PMID 782220. doi:10.1016/s0002-8703(76)80114-7.
- ^ Velasco, M; Gilbert, CA; Rutledge, CO; McNay, JL. Antihypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: A comparison with hydralazine. Clinical Pharmacology and Therapeutics. 1975, 18 (2): 145–53. PMID 1097150. S2CID 19966617. doi:10.1002/cpt1975182145.
- ^ Velasco, M.; McNay, J. L. Physiologic mechanisms of bupicomide- and hydralazine-induced increase in plasma renin activity in hypertensive patients.. Mayo Clinic Proceedings. 1977, 52 (7): 430–2. PMID 875465.